ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016
[Clinical Significance of Tumor Marker Detection in Patients with Advanced Squamous Cell Carcimoma of the Lung].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to it's concealment and no obvious symptoms, lung squamous carcimoma often has advanced disease when diagnosed. The aims of this study were to describe the characteristics of the disease, to evaluate the clinical importance of detection of multiple tumor markers in patients with squamous cell carcinoma of the lung.
methodsThe characteristics of all patients with advanced squamous cell lung cancer treated in Beijing Cancer Hospital of Chinese Academy of Medical Sciences during Jan. 2011 to Dec. 2015 were identified by cases reviewing and data extracting. The characteristics, detection levels and sensitivity of multiple tumor makers among patients were described.
resultsThe 260 patients were treated with mean age of (59.4±9.2) years, 85.8% (n=223) of them were male, 14.2% (n=37) of them were female. 78.1% (n=203) of all were smokers and 3.1% (n=8) of patients had family history of tumor. The positive rate of cytokerantin 19 fragment (CYFRA21-1) was 71.2%, which was the highest among five tumor markers. The five tumor markers median level had no statistical significance between different tumor (T) stages and node (N) stages (all P>0.05), only the positive rate of SCC had statistical significance between different T stages (P=0.035). The combination measurement of CYFRA21-1+carcinogen-embryonic antigen (CEA), CYFRA21-1+CEA+cancer antigen (CA125), CA125+CYFRA21-1+CEA+neuron specific enolase (NSE), and CA125+CYFRA21-1+NSE+CEA+squamous cell carcinoma antigen (SCC) were better and had higher clinical values, the positive rates were 82.7%, 84.6%, 85.0% and 86.2%, respectively.
conclusionsThe positive rate of CYFRA21-1 was the highest and the sensitivity of single test of five tumor markers was low, the combination of multiple tumor markers increased the sensitivity of diagnosis of SQCLC, the combination of CA125, CYFRA21-1 and CEA was the best choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.